QNRX vs. CTCX, QTI, BTCY, AEMD, CHEK, ICU, POAI, NURO, CUTR, and MHUA
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Carmell (CTCX), QT Imaging (QTI), Biotricity (BTCY), Aethlon Medical (AEMD), Check-Cap (CHEK), SeaStar Medical (ICU), Predictive Oncology (POAI), NeuroMetrix (NURO), Cutera (CUTR), and Meihua International Medical Technologies (MHUA). These companies are all part of the "medical equipment" industry.
Quoin Pharmaceuticals vs.
Quoin Pharmaceuticals (NASDAQ:QNRX) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Quoin Pharmaceuticals' return on equity of -125.60% beat Carmell's return on equity.
In the previous week, Quoin Pharmaceuticals and Quoin Pharmaceuticals both had 2 articles in the media. Quoin Pharmaceuticals' average media sentiment score of 1.11 beat Carmell's score of -0.33 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.
Quoin Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Quoin Pharmaceuticals received 5 more outperform votes than Carmell when rated by MarketBeat users.
Quoin Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 600.28%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Quoin Pharmaceuticals is more favorable than Carmell.
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.2% of Carmell shares are owned by institutional investors. 3.7% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 29.0% of Carmell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Quoin Pharmaceuticals beats Carmell on 8 of the 11 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:QNRX) was last updated on 1/21/2025 by MarketBeat.com Staff
